Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immune checkpoint

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    196 result(s) found for: Immune checkpoint. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-001915-35 Sponsor Protocol Number: 08052017 Start Date*: 2017-09-15
    Sponsor Name:Medical University of Graz
    Full Title: GLUCOCORTICOID HIGH-DOSE VS. REPLACEMENT IN IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HYPOPHYSITIS: AN OPEN, RANDOMIZED PILOT STUDY
    Medical condition: Immune regulatory antibodies (e.g. ipilimumab, pembrolizumab and nivolumab) inhibiting immunological checkpoints are increasingly used to treat various oncological entities. Potential side effects ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001270-34 Sponsor Protocol Number: RIMAL1 Start Date*: 2021-04-19
    Sponsor Name:Radboud University Medical Centre
    Full Title: Enhancement of immune response by combining immune checkpoint blockade and radiation in patients with recurrent / refractory malignant lymphoma (re-directing the immune system).
    Medical condition: patients with recurrent / refractory 9p24.1 amplified malignant lymphomas patients with recurrent / refractory malignant lymphoma without 9p24.1 amplification
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025310 Lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000157-27 Sponsor Protocol Number: INCB86550-203 Start Date*: 2020-08-25
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid Tumors
    Medical condition: Immune Checkpoint Inhibitor–Naïve Selected Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-005613-14 Sponsor Protocol Number: REUM-2021-01 Start Date*: 2023-03-13
    Sponsor Name:
    Full Title: Immune-Related Rheumatological Adverse Events study. Data collection from patients with cancer to evaluate rheumatological adverse events in patients treated with immune-checkpoint inhibitors.
    Medical condition: Any cancer patients starting immune checkpoint inhibitor therapy (ICI-therapy). Any patient exhibiting a rheumatological immune-related adverse event (R-irAE). Patients with newly developed rheum...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000708-10 Sponsor Protocol Number: CPZP034A2410 Start Date*: 2017-09-18
    Sponsor Name:Novartis Pharma AG
    Full Title: A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma ...
    Medical condition: Advanced and/or metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10068208 Renal neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Ongoing) AT (Completed) GB (GB - no longer in EU/EEA) HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-001197-28 Sponsor Protocol Number: 201900180 Start Date*: 2019-07-31
    Sponsor Name:University Medical Center Groningen
    Full Title: Can 89Zr-atezolizumab PET scan identify patients with metastatic invasive lobular breast cancer who will respond to chemotherapy-immune checkpoint inhibition?
    Medical condition: Lobular metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001811-94 Sponsor Protocol Number: M18-868 Start Date*: 2022-01-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Adva...
    Medical condition: C-Met overexpressing EGFR wildtype, non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) BE (Trial now transitioned) HU (Completed) FR (Trial now transitioned) RO (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000040-30 Sponsor Protocol Number: 202100912 Start Date*: 2023-03-06
    Sponsor Name:University Medical Center Groningen
    Full Title: An open label pilot study of [18AlF]-Resca-IL2 (Interleukin-2 PET tracer) for positron emission tomography imaging in patients treated with immune checkpoint inhibitors.
    Medical condition: patients with stage IV non-small-cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), CSCC, urothelial cell cancer (UCC), and head and neck squamous cell carcinoma (HNSCC), eligible for ICI the...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002595-41 Sponsor Protocol Number: AA1820 Start Date*: 2018-09-05
    Sponsor Name:Herlev and Gentofte Hospital
    Full Title: CHECKPOINT INHIBITOR INDUCED COLITIS AND ARTHRITIS – IMMUNOMODULATION WITH IL-6 BLOCKADE AND EXPLORATION OF DISEASE MECHANISMS
    Medical condition: Immune therapy related adverse events (arthritis and colitis) in patients with solid tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009887 Colitis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10003246 Arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-002860-29 Sponsor Protocol Number: ONC-2019-002 Start Date*: 2019-12-12
    Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS
    Full Title: Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A Phase II study (Immunocabo).
    Medical condition: Hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003048-22 Sponsor Protocol Number: Uni-Koeln-3571 Start Date*: 2020-06-16
    Sponsor Name:Universität zu Köln
    Full Title: A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal...
    Medical condition: locally advanced esophageal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001173 Adenocarcinoma of esophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004623-17 Sponsor Protocol Number: 26092020 Start Date*: 2021-11-09
    Sponsor Name:Zealand University Hospital
    Full Title: Irreversible electroporation in combination with immune checkpoint inhibi-tion , in patients with metastatic pancreatic cancer - A prospective, phase 2 study
    Medical condition: Patients with non-curable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003613-19 Sponsor Protocol Number: APHP210303 Start Date*: 2021-12-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: AbataCept for the treatment of immune-cHeckpoint inhibitors induced mYocarditiS
    Medical condition: All adult patients with cancer (all cancer types) treated by immune checkpoint inhibitors (anti-PD1, anti-PDL1, anti-CTLA4 monotherapies or combination) and presenting drug-induced myocarditis. The...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001273-81 Sponsor Protocol Number: EFC15858 Start Date*: 2019-12-17
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Randomized, Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic Non-Squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors
    Medical condition: Non-small cell lung cancer metastatic
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) HU (Prematurely Ended) DE (Completed) PL (Completed) PT (Completed) BE (Completed) ES (Prematurely Ended) GR (Completed) BG (Completed) FR (Trial now transitioned) IT (Completed) RO (Ongoing) LT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002300-27 Sponsor Protocol Number: SPON1529-16 Start Date*: 2019-09-13
    Sponsor Name:Cardiff University
    Full Title: Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III Squamous Cell Carcinoma of Anus
    Medical condition: Locally advanced (stage IIIA/B, T3/T4, any N,M0) anal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061424 Anal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-005793-10 Sponsor Protocol Number: 01012121 Start Date*: 2021-07-08
    Sponsor Name:Jakob Benedict Seidelin
    Full Title: Open label Randomized Controlled clinical Trial of vedolizumab versus conventional treatment for Checkpoint Inhibitor induced Colitis
    Medical condition: Immune check point inhibitor induced colitis
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004856 10082455 Immune-mediated colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004003-39 Sponsor Protocol Number: 2018-BN-001 Start Date*: 2018-12-19
    Sponsor Name:UZ Brussel
    Full Title: A stratified dual-arm open-label two-stage phase 2 trial of trametinib in patients with advanced pretreated BRAFV600 wild-type melanoma
    Medical condition: ADVANCED PRETREATED BRAFV600 WILD-TYPE MELANOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    20.0 100000004864 10027150 Melanoma malignant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003565-10 Sponsor Protocol Number: SAKK06/17 Start Date*: 2018-12-03
    Sponsor Name:Swiss Group for Clinical Cancer Research
    Full Title: Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A multicenter, single-arm phase II Trial.
    Medical condition: muscle invasive urothelial cancer (MIUC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003555-16 Sponsor Protocol Number: 21469 Start Date*: 2020-12-11
    Sponsor Name:BAYER AG
    Full Title: An Open-Label Study of Regorafenib in Combination with Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) after PD-1/PD-L1 Immune Checkpoint Inhibitors
    Medical condition: A type of liver cancer which may have spread to nearby tissue and is unlikely to be cured or controlled with treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-001250-21 Sponsor Protocol Number: 2020/3078 Start Date*: 2020-04-03
    Sponsor Name:GUSTAVE ROUSSY
    Full Title: COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients
    Medical condition: Patients eligible for, or under, or recently treated by chemotherapy (CT) and/or immune-checkpoint blockade (ICB) for the treatment of solid tumors or hematological malignancies.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 09:52:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA